Nature Biomedical EngineeringNeurosciencePeer-reviewed journal article
Large-scale visualisation of α-synuclein oligomers in Parkinson's disease brain tissue
Rebecca AndrewsiD, Bin FuiD, Christina E. ToomeyiD, Jonathan C. BreiteriD, Joanne LachicaiD, Joseph S. BeckwithiD, Ru TianiD, Emma E. BrockiD, Lisa-Maria NeedhamiD, Gregory J. ChantiD, Camille LoiseauiD, Angèle DeconfiniD, Kenza BaspiniD, Rebeka PopoviciD, James EvansiD, Yee Yen Goh, Begüm Kurt, Lenart Senicar, Marisa J. EdmondsiD, Tim BartelsiD, Nora Bengoa‐VergnioryiD, Peter J. MagilliD, Zane JaunmuktaneiD, Oliver J. FreemaniD, Ben TayloriD, , Steven F. LeeiD
Abstract
Parkinsons disease (PD) is a common neurodegenerative condition characterised by the presence in the brain of large intraneuronal aggregates, known as Lewy bodies and Lewy neurites, containing fibrillar -synuclein. According to the amyloid hypothesis, these large end-stage species form from smaller soluble protein assemblies, often termed oligomers, which are proposed as early drivers of pathogenesis. To date, however, this hypothesis has remained controversial, at least in part because it has not been possible to directly visualise oligomeric aggregates in human brain tissue. Therefore, their presence, abundance and distributions have remained elusive. Here, we present ASA-PD (Advanced Sensing of Aggregates - Parkinsons Disease), an imaging method to generate large-scale -synuclein oligomer maps in post-mortem human brain tissue. We combined autofluorescence suppression with single-molecule fluorescence methods, which together, enable the detection of nanoscale -synuclein aggregates. To demonstrate the utility of this platform, we captured [~]1.2 million oligomers from the anterior cingulate cortex in human post-mortem brain samples from PD and healthy control patients. Our data revealed a specific subpopulation of nanoscale oligomers that represent an early hallmark of the proteinopathy that underlies PD. We anticipate that quantitative information about oligomer distributions provided by ASA-PD will enable mechanistic studies to reveal the pathological processes caused by -synuclein aggregation.
- Citations
- 26
- FWCI
- 14.52
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- α-Synuclein driven cell susceptibility in Parkinson's disease
Jonathan C. Breiter, Joseph S. Beckwith, … Steven F. Lee·bioRxiv·Aug 19, 2025
- Super-resolution microscopy of nanoscopic alpha-synuclein aggregates in brain samples indicates a subset of cells have disrupted protein homeostasis prior to Lewy body formation in Parkinson's disease
Emre Fertan, John S. H. Danial, … David Klenerman·bioRxiv·Sep 16, 2025
- Phospholipids Uniquely Modify Secondary Structure of α-Synuclein Oligomers
T. Dou, L. Zhou, D. Kurouski·bioRxiv·Jan 15, 2021
- Imaging α-synuclein pathologies in animal models and patients with Parkinson's and related diseases
Hironobu Endo, Maiko Ono, … Makoto Higuchi·NeuronPeer-reviewed·Jun 5, 2024
- Lewy pathology in Parkinson's disease consists of a crowded organellar, membranous medley
Sarah H. Shahmoradian, Amanda J. Lewis, … Matthias E. Lauer·Nature NeurosciencePeer-reviewed·Jun 24, 2019
- Endogenous α-SYN protein analysis from human brain tissues using single-molecule pull-down assay